文献速递炎症性肠病

晚期疗法实现克罗恩病内镜结局疗效比较:系统评价与网络荟萃分析

Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-01-06

该系统评价与网络荟萃分析纳入20项随机对照试验共5592例中重度活动性克罗恩病患者,比较晚期疗法诱导和维持内镜缓解的疗效。JAK1抑制剂和抗IL23p19药物在诱导内镜应答方面可能最有效,除维得利珠单抗外所有药物均能有效维持内镜缓解。

要点

  • JAK1抑制剂诱导内镜应答优于etrolizumab(RR 3.49)和抗IL12/23p40药物(RR 2.34)。
  • 抗IL23p19药物诱导内镜应答优于etrolizumab(RR 2.30)。
  • 维持内镜缓解方面,除维得利珠单抗外所有药物均优于安慰剂。

核心结论

  • 网络荟萃分析显示,JAK1抑制剂和抗IL23p19药物在非TNF靶向晚期疗法中诱导内镜应答可能最有效。
  • 未来头对头试验将进一步指导不同疗法在克罗恩病管理中的定位。

研究设计与样本

  • 系统评价与网络荟萃分析,检索MEDLINE、Embase和Cochrane CENTRAL数据库从建库至2023年8月2日。
  • 纳入20项随机对照试验(19项安慰剂对照和1项头对头试验),共5592例≥18岁中重度活动性克罗恩病患者。
  • 12项RCT报告诱导期内镜结局,5项报告维持期,3项同时报告诱导和维持期。
  • 采用频率学方法进行随机效应网络荟萃分析,估计相对风险(RR)、95%置信区间(CI)和P评分用于排序。
  • 使用GRADE评估证据确定性。

主要发现

  • JAK1抑制剂诱导内镜应答优于etrolizumab(RR 3.49,95% CI 1.48-8.26;中等确定性证据)。
  • 抗IL23p19药物诱导内镜应答优于etrolizumab(RR 2.30,95% CI 1.02-5.18;中等确定性证据)。
  • JAK1抑制剂诱导内镜应答优于抗IL12/23p40药物(RR 2.34,95% CI 1.14-4.80;中等确定性证据)。
  • JAK1抑制剂和抗IL23p19药物在诱导内镜应答方面排名最高。
  • 维持内镜缓解的网络荟萃分析纳入6项RCT,除维得利珠单抗(RR 1.89,95% CI 0.61-5.92)外,所有药物均优于安慰剂。

关键数值与推荐

  • 主要结局为诱导治疗后内镜应答和维持治疗后内镜缓解。
  • JAK1抑制剂诱导内镜应答优于etrolizumab:RR 3.49(95% CI 1.48-8.26),中等确定性证据。
  • 抗IL23p19药物诱导内镜应答优于etrolizumab:RR 2.30(95% CI 1.02-5.18),中等确定性证据。
  • JAK1抑制剂诱导内镜应答优于抗IL12/23p40药物:RR 2.34(95% CI 1.14-4.80),中等确定性证据。
  • 维得利珠单抗维持内镜缓解与安慰剂比较:RR 1.89(95% CI 0.61-5.92)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 报告诱导治疗内镜结局的TNF拮抗剂RCT缺乏。
  • 未来需头对头试验进一步指导不同疗法的定位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We conducted a network meta-analysis to compare the efficacy of advanced therapies for achieving endoscopic outcomes in patients with moderate-to-severely active Crohn's disease. METHODS: MEDLINE, Embase, and Cochrane CENTRAL databases were searched from inception to August 2, 2023 to identify phase II and III randomized controlled trials (RCTs) in adults (≥18 years) with moderate-to-severe Crohn's disease treated with tumor necrosis factor (TNF) antagonists, etrolizumab, vedolizumab, anti-interleukin (IL)12/23p40, anti-IL23p19, or Janus kinase-1 (JAK1) inhibitors, compared with placebo/active comparator, for induction and/or maintenance of remission and reported endoscopic outcomes. Primary outcome was endoscopic response after induction therapy, and endoscopic remission after maintenance therapy. We performed a random-effects network meta-analysis using a frequentist approach, and estimated relative risk (RRs), 95% confidence interval (CI) values, and P score for ranking agents. We used GRADE to ascertain certainty of evidence. RESULTS: A total of 20 RCTs (19 placebo-controlled and 1 head-to-head trial; 5592 patients) were included out of which 12 RCTs reported endoscopic outcomes for the induction phase, 5 reported for the maintenance phase, and 3 reported for both induction and maintenance phases. JAK1 inhibitors (RR, 3·49 [95% CI, 1·48-8·26]) and anti-IL23p19 (RR, 2·30 [95% CI, 1·02-5·18]) agents were more efficacious than etrolizumab (moderate certainty of evidence), and JAK1 inhibitors (RR, 2·34 [95% CI, 1·14-4·80]) were more efficacious than anti-IL12/23p40 agents for inducing endoscopic response (moderate certainty of evidence). JAK1 inhibitors and anti-IL23p19 ranked highest for induction of endoscopic response. There was paucity of RCTs of TNF antagonists reporting endoscopic outcomes with induction therapy. On network meta-analysis of 6 RCTs, all agents except vedolizumab (RR, 1.89 [95% CI, 0.61-5.92]) were effective in maintaining endoscopic remission compared with placebo. TNF antagonists, IL12/23p40, and JAK1 inhibitors were ranked highest. CONCLUSIONS: On network meta-analysis, JAK1 inhibitors and anti-IL23p19 agents may be the most effective among non-TNF-targeting advanced therapies for inducing endoscopic response. Future head-to-head trials will further inform positioning of different therapies for the management of Crohn's disease.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Vuyyuru SK, Nguyen TM, Murad MH, et al. Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis. Clin Gastroenterol Hepatol. 2024. PMID: 38185396. doi:10.1016/j.cgh.2023.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。